newsfilter
← Latest News
GlobeNewswire·

Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases

Avalon and research partner, University of Natural Resources and Life Sciences (BOKU), in Vienna, Austria, co-develop a novel technology to efficiently synthesize and study previously difficult to work with drug targets Technology will facilitate drug